Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus and temozolomide as first-line treatment in advanced gastrointestinal neuroendocrine carcinoma (G3) with Ki67 20–55%
2013-002524-16Phase 2Completed
- Sponsor
- Haukeland University Hospital
- Start
- Sep 2013
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus and temozolomide in gastrointestinal neuroendocrine carcinoma (GI-NEC), sponsored by Haukeland University Hospital. Primary endpoint: Disease control rate at 6 months. Started Sep 2013; status: completed.
02
Drugs
everolimustemozolomide
03
Conditions
gastrointestinal neuroendocrine carcinoma (GI-NEC)
Beyond the preview
Go deeper on 2013-002524-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002524-16.